Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 17/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886968 | 0.91 | ICMT (0.63) | ICMTOPRM1OPRK1 | |
| SCHEMBL18887117 | 0.91 | ICMT (0.61) | ICMTOPRM1OPRK1 | |
| SCHEMBL18886982 | 0.87 | OPRM1 (0.59) | ICMTOPRM1OPRK1 | |
| SCHEMBL18887068 | 0.82 | ICMT (0.60) | ICMTOPRM1OPRK1 | |
| SCHEMBL12614616 | 0.82 | ICMT (0.63) | ICMTOPRM1 | |
| SCHEMBL18886932 | 0.81 | OPRM1 (0.63) | ICMTOPRM1 | |
| SCHEMBL18887064 | 0.80 | OPRM1 (0.64) | ICMTOPRM1OPRK1 | |
| SCHEMBL18887108 | 0.78 | ICMT (0.63) | ICMTOPRM1 | |
| SCHEMBL18886901 | 0.78 | OPRM1 (0.65) | ICMTOPRM1 | |
| SCHEMBL18887021 | 0.78 | OPRM1 (0.64) | ICMTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588889-B2 | Methods of treating hyperalgesia | TREVENA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3290415-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | Trevena, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170333385-A1 | Methods of Treating Hyperalgesia | TREVENA, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333385-A1 | Methods of Treating Hyperalgesia | OPRL1, OPRK1, CHAT | ICMT 3127/4885OPRM1 35/4885OPRK1 2/4885 |
| US-10588889-B2 | Methods of treating hyperalgesia | OPRL1, OPRK1, CHAT | ICMT 3127/4885OPRM1 35/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.